Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)

Autor:	Akihiro Bessho, Tomoya Fukui, Nobuhiko Seki, Jiichiro Sasaki, Akinobu Hamada, Satoshi Igawa, Katsuhiko Naoki, Noriyuki Masuda, Yoshiro Nakahara, Hiroaki Okamoto, Shinobu Hosokawa, Nobuaki Fukamatsu, Yukiko Nakamura, Takaaki Tokito, Takashi Kasai, Tomohide Sugiyama, Sakiko Otani
Rok vydání:	2020
Předmět:	0301 basic medicine Oncology Adult Male medicine.medical_specialty Lung Neoplasms Combination therapy Phases of clinical research Antineoplastic Agents 03 medical and health sciences Erlotinib Hydrochloride 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Clinical endpoint Humans Pharmacology (medical) Anthracyclines Epidermal growth factor receptor Lung cancer Aged Pharmacology biology business.industry Middle Aged medicine.disease Progression-Free Survival Clinical trial ErbB Receptors 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Erlotinib business Amrubicin medicine.drug
Zdroj:	Investigational new drugs. 39(2)
ISSN:	1573-0646 0000-1058
Popis:	Background Amrubicin (AMR) is a completely synthetic 9-aminoanthracycline and clinically active against non-small cell lung cancer (NSCLC). We conducted a phase I study of AMR and erlotinib (ERL) combination therapy in previously treated patients with advanced NSCLC and have already reported the safety and effectiveness. Methods We conducted a multi-center, single-arm phase II trial to evaluate the efficacy of AMR and ERL combination therapy in patients with previously treated, advanced NSCLC harboring wild-type EGFR, PS 0–1 and
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8534c99c0ac043914941e0d0397e8f5 https://pubmed.ncbi.nlm.nih.gov/33159674 Zobrazit plný text záznamu Full text from SpringerLink